Finanzen von Sionna Therapeutics Inc (SION)SIONSionna Therapeutics Inc

Evaluating the bottom line, Sionna Therapeutics, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -32.34%, provide a clear picture of how effectively SION converts its operational activities into shareholder value.

In the context of the broader market, SION competes directly with industry leaders such as SRZN and WHWK. With a market capitalization of $239.17M, it holds a significant position in the sector. When comparing efficiency, SION's gross margin of N/A stands against SRZN's N/A and WHWK's N/A. Such benchmarking helps identify whether Sionna Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Sionna Therapeutics has reported consistent net losses, with a projected net income loss of -29,886,000 USD for Q2 2026. The forward P/E ratio is 0, reflecting no earnings expectations in the near future.